{"id":231277,"date":"2025-07-02T06:15:20","date_gmt":"2025-07-02T06:15:20","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/231277\/"},"modified":"2025-07-02T06:15:20","modified_gmt":"2025-07-02T06:15:20","slug":"clinical-genomics-market-surges-in-2025-with-nabl-accredited-molecular-labs-and-ai-integrated-platforms","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/231277\/","title":{"rendered":"Clinical Genomics Market Surges in 2025 with NABL-Accredited Molecular Labs and AI-Integrated Platforms"},"content":{"rendered":"

<\/p>\n

The global clinical
\ngenomics market<\/b><\/a> is valued at approximately US$1.06 billion in 2024 and
\nis expected to rise to US$1.25 billion in 2025. Looking ahead, the market is
\nprojected to reach around US$5.34 billion by 2034, expanding at a robust CAGR
\nof 17.54% from 2025 to 2034.<\/p>\n

<\/p>\n

Get a free preview of the Clinical
\nGenomics Market report, featuring key insights and trends: <\/b>https:\/\/www.towardshealthcare.com\/download-sample\/5754<\/b><\/a><\/p>\n

Growing instances of genetic diseases and
\ncancer, advancements
\nin genomic<\/b><\/a> technologies, including next-generation
\nsequencing<\/b><\/a> (NGS), and rising
\ndemand for precision medicine<\/b><\/a> are driving the global clinical genomics
\nmarket. Furthermore, boosting awareness about the advantages of genomic testing
\namong patients and healthcare providers is accelerating the market growth. It
\nmainly encompasses early disease detection, better treatment selection, and enhanced
\npatient outcomes.\u00a0Besides this, government initiatives and escalated
\ninvestments in genomic research and development are propelling the further
\nmarket expansion. <\/p>\n

Clinical Genomics Market Highlights:<\/b><\/p>\n

\u2022\u00a0 The clinical genomics sector is pushing
\nthe market to USD 1.06 billion in 2024.<\/p>\n

\u2022\u00a0 Long-term projections show a USD 5.34
\nbillion valuation by 2034.<\/p>\n

\u2022\u00a0 Growth is expected at a steady CAGR of
\n17.54% between 2025 to 2034.<\/p>\n

\u2022\u00a0 North America led the global clinical
\ngenomics market share in 2024.<\/p>\n

\u2022\u00a0 Asia Pacific\u202fis expected to register the
\nfastest growth in the projected period.<\/p>\n

\u2022\u00a0 By test type, the diagnostic testing
\nsegment was dominant in the market in 2024.<\/p>\n

\u2022\u00a0 By test type, the genetic testing
\nsegment is expected to grow at the fastest CAGR during the forecast period.<\/p>\n

\u2022\u00a0 By method type, the biochemical tests
\nsegment held a major revenue share of the market in 2024.<\/p>\n

\u2022\u00a0 By method type, the molecular tests
\nsegment is expected to be the fastest growing during 2025-2034.<\/p>\n

\u2022\u00a0 By end user, the hospitals & clinics
\nsegment held the dominating revenue share of the global clinical genomics
\nmarket in 2024.<\/p>\n

\u2022\u00a0 By end user, the academic and research
\ninstitutes segment is expected to grow fastest in the upcoming years. <\/p>\n

Access detailed market data, segment
\nanalysis, and growth projections in our exclusive databook: <\/b>https:\/\/www.towardshealthcare.com\/download-databook\/5754<\/b><\/a><\/p>\n

Market Overview <\/b><\/p>\n

Clinical genomics is a branch of genomics
\nin which information from an individual patient’s genome is used to inform
\nclinical decision-making. Primarily, this clinical genomics market is fueled by
\nthe increasing cases of cancer, genetic diseases, and infectious conditions
\nthat need advanced genomic analysis for diagnosis and prognosis, and treatment,
\nalong with advancements in technologies, including NGS, long-read
\nsequencing<\/b><\/a>, and CRISPR, are providing cost-effective, rapid, and
\naccessible solutions. As well as Integrating
\nAI with genomics is a major emerging trend<\/b><\/a> that can boost research
\nactivities and enhance diagnostics.\u00a0 <\/p>\n

Widespread Applications in Diagnostics
\nand Drug Development: Major Potential <\/b><\/p>\n

Clinical genomics has various opportunities
\nacross the globe, including its high use to diagnose different conditions like
\ngenetic disorders, cancer, infectious diseases, and prenatal
\nconditions.\u00a0Along with this, in the drug
\ndiscovery and development area<\/b><\/a>, it helps to determine drug targets,
\nestimate drug responses, and develop novel drug candidates. Clinical-based
\ngenomics supports to analysis individual’s genome, and clinicians can choose
\nthe highly efficacious and safe medications and therapies, which further
\nenhance the development
\nof personalized medicine<\/b><\/a>. <\/p>\n

Accelerating Expenditure on Technology
\nand Infrastructure: Major Limitation<\/b><\/p>\n

In the clinical genomics market, for the
\nsettings and maintenance of genomic facilities, major investments are needed in
\nspecialized reagents and bioinformatics
\ninfrastructure<\/b><\/a>, which is generating limitations for smaller
\ninstitutions and healthcare facilities. Also, a shortage of skilled
\nprofessionals in areas including bioinformatics, data analysis, and
\ninterpretation creates a barrier to market expansion. <\/p>\n

You can place an order or ask any
\nquestions, please feel free to contact us at <\/b>sales@towardshealthcare.com<\/b><\/a><\/p>\n

The Clinical Genomics Market: Regional
\nAnalysis<\/b><\/p>\n

North America dominated the market with the
\nbiggest revenue share in 2024. The respective market is driven by the growing
\nincidence of chronic and inherited diseases such as cancer, cardiovascular
\ndiseases, and genetic disorders, which increasingly demand advanced diagnostic
\nand treatment solutions offered by clinical genomics. Also, this region is
\nadvancing NGS technology with cost-effective and accessible solutions, allowing
\nlarge-scale genomic studies and fueling its adoption in clinical settings for
\ndiagnostics and research.<\/p>\n

The most influential country in North
\nAmerica is the US, which is widely adopting personalized medicine by detecting
\ngenetic markers that indicate disease risks, supporting treatment decisions,
\ndue to the major role of clinical genomics in these results in the development
\nof targeted therapies<\/b><\/a>. Besides this, NIH’s funding for genomic research
\nis significantly contributing to the clinical genomics market growth. <\/p>\n

Whereas, Canada is stepping towards
\nawareness among healthcare professionals and the public about adoption and
\ngreater application of genomics which resulting in raised demand for genomic
\nservices in hospitals and clinics. As well as the Canadian government is
\nincreasingly investing in genomic research and infrastructure, such as the
\nCanadian Genomics Strategy, which is driving the ultimate market growth. <\/p>\n

The Asia Pacific is Anticipated to Grow
\nat a Rapid CAGR During the Forecast Period<\/b><\/p>\n

Rising different health concerns like
\ngenetic disorders, heart diseases, diabetes, and infectious diseases such as
\nCOVID-19 are widely demanding highly effective and safe personalized therapies
\nASAP. This demand is resulting in the fastest clinical genomics market growth. As
\nwell as ASAP is developing less expensive NGS technology for more approachable
\nto various laboratories and research institutions. <\/p>\n

Mainly, China is experiencing major growth
\ndue to the rising
\nadoption of biotechnologies<\/b><\/a> in various aspects of health, also they are
\nputting efforts to develop innovative therapies for genetic disorders. Also,
\nthe Chinese government is emphasizing boosting awareness about health concerns
\nand funding for R&D in biology collaborations
\nwith different biopharmaceutical<\/b><\/a> and bioinformatics companies. <\/p>\n

Whereas India has numerous opportunities in
\nclinical genomics, as the number of cases is increasing. Also, India is greatly
\nadopting novel technologies like NGS and CRISPR to develop patient-based,
\ntailored medicines for genetic concerns, diabetes, and heart diseases. <\/p>\n

Get the latest insights on life science
\nindustry segmentation with our Annual Membership: <\/b>https:\/\/www.towardshealthcare.com\/get-an-annual-membership<\/b><\/a><\/p>\n

Recent Updates of ASAP Countries <\/b><\/p>\n\n\n

Company or Country<\/b><\/p>\n<\/td>\n\n

Recent Updates<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

China (February 2025)<\/p>\n<\/td>\n\n

Launched an AI model, PUMCH-GENESIS, to diagnose rare diseases.<\/p>\n<\/td>\n<\/tr>\n\n\n

Japan\u2019s ELECOM (February 2025)<\/p>\n<\/td>\n\n

MediBuddy partnered with Japan\u2019s ELECOM to launch Smart Health IoT
\n Devices in India.<\/p>\n<\/td>\n<\/tr>\n\n\n

India (February 2025)<\/p>\n<\/td>\n\n

IIT Madras unveiled a public access cancer genome database to
\n support cancer research, drug discovery in India. <\/p>\n<\/td>\n<\/tr>\n\n\n

Japan (January 2025)<\/p>\n<\/td>\n\n

Taiwan’s advanced genomics and cancer precision medicine
\n collaborated to launch a bladder cancer screening test in Japan.<\/p>\n<\/td>\n<\/tr>\n\n\n

ACT Genomics (July 2024)<\/p>\n<\/td>\n\n

ACT Genomics and LSI Medience signed an MOU to form a partnership
\n and collaborate in the Japanese market.<\/p>\n<\/td>\n<\/tr>\n

\u00a0<\/p>\n

The Clinical Genomics Market
\nSegmentation Analysis<\/b><\/p>\n

By test type analysis<\/b><\/p>\n

The diagnostic testing segment dominated
\nthe market in 2024. Major impacting factor is rising cases of cancer,
\ncardiovascular diseases, and genetic disorders which demand for early and
\nprecise diagnosis is critical for effective management and treatment of these
\nconditions, making genomic testing an essential tool and accelerating demand
\nfor diagnostic testing.\u00a0<\/p>\n

Whereas the genetic testing segment is
\nexpected to grow rapidly during 2025-2034. The growing development of faster
\nand affordable
\nsequencing techniques<\/b><\/a> like NGS for complete genomes or specific gene
\npanels is fueling demand for applications of genetic testing. As well as
\npolymerase chain reaction (PCR) technology supports as a consistent and vital
\ntool for genetic testing segment growth.<\/p>\n

By method type analysis<\/b><\/p>\n

The biochemical tests segment was dominant
\nin the clinical genomics market in 2024. Applications of biochemical tests are
\nvital in the identification of genetic and metabolic concerns in newborns,
\nenabling prior intervention and management is a major driver of this segment’s
\ngrowth. Also, these tests enhance timely treatments and optimize patient
\nresults, along with their cost-effectiveness property over some advanced
\ngenomic techniques, making them a preferred choice for a large-scale screening
\nprocess. <\/p>\n

On the other hand, the molecular tests
\nsegment is predicted to register the fastest growth in the upcoming years.
\nGroundbreaking technologies such as PCR, NGS, and point-of-care testing have
\nenhanced the capabilities and uses of molecular tests by allowing more accurate
\nand robust testing is propelling the segment and market expansion. Molecular
\ntests are also playing a major role in the development of precision medicine by
\ndetecting specific genetic markers. <\/p>\n

By end-user analysis<\/b><\/p>\n

The hospitals & clinics segment led the
\nglobal clinical genomics market in 2024. However, hospitals and clinics possess
\nthe integration of genomic testing into routine care, such as hereditary cancer
\nscreening, pharmacogenomics, rapid sequencing in neonatal intensive care units
\n(NICUs), and oncology
\ncenters<\/b><\/a>. Along with improved healthcare facilities and government
\nsupport is boosting the segment expansion.<\/p>\n

The academic and research institutes
\nsegment is anticipated to show the fastest growth during the forecast period.
\nPrimarily, both the government and private sectors are investing increasingly
\nin genomic research, allowing important financial support to academic and
\nresearch institutions. Besides this, these institutions are employing genomics
\nservices to study gene structure, function, and variations, resulting in
\ndiscoveries and advancements in healthcare.\u00a0<\/p>\n

Elevate your
\nhealthcare strategy with Towards Healthcare. Enhance efficiency and drive
\nbetter outcomes schedule a call today: <\/b><\/a>https:\/\/www.towardshealthcare.com\/schedule-meeting<\/b><\/a><\/p>\n

Top 10 Companies and Their Contributions
\nto the Market<\/b><\/p>\n\n\n

Company<\/b><\/p>\n<\/td>\n\n

Latest Contribution \/ Offering<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Illumina, Inc.<\/b><\/p>\n<\/td>\n\n

Continues to power precision medicine with its global NGS
\n platforms and actively supports comprehensive genomic profiling for research
\n and diagnostics.<\/p>\n<\/td>\n<\/tr>\n\n\n

Quest Diagnostics<\/b><\/p>\n<\/td>\n\n

Expands precision oncology with its Haystack MRD liquid biopsy and
\n Alzheimer\u2019s blood biomarkers p\u2011tau217\/p\u2011tau181 tests.<\/p>\n<\/td>\n<\/tr>\n\n\n

PerkinElmer, Inc.<\/b><\/p>\n<\/td>\n\n

Drives high-throughput clinical genomics via automated assay
\n systems used in major diagnostic laboratories worldwide.<\/p>\n<\/td>\n<\/tr>\n\n\n

Eurofins Scientific SE<\/b><\/p>\n<\/td>\n\n

Delivers large-scale NGS and bioinformatics services through
\n Eurofins Genomics to thousands of clients globally.<\/p>\n<\/td>\n<\/tr>\n\n\n

Rosetta Genomics Ltd.<\/b><\/p>\n<\/td>\n\n

Leads in miRNA-based diagnostics for lung and other cancers,
\n offering assays for clinical decision support.<\/p>\n<\/td>\n<\/tr>\n\n\n

NeoGenomics Inc.<\/b><\/p>\n<\/td>\n\n

Debuted the PanTracer tumor profiling suite and Paletrra spatial\u2011proteomics
\n platform at ASCO\u202f2025 for advanced cancer diagnostics.<\/p>\n<\/td>\n<\/tr>\n\n\n

Invitae Corporation<\/b><\/p>\n<\/td>\n\n

Strengthens its focus on hereditary and reproductive testing under
\n the pending LabCorp acquisition.<\/p>\n<\/td>\n<\/tr>\n\n\n

Foundation Medicine, Inc.<\/b><\/p>\n<\/td>\n\n

Supports precision oncology through its comprehensive genomic
\n profiling assays integrated into partner workflows.<\/p>\n<\/td>\n<\/tr>\n\n\n

Genomic Health, Inc.<\/b><\/p>\n<\/td>\n\n

Exact Sciences continues to deliver Oncotype\u202fDX breast\u2011cancer
\n recurrence testing across diverse populations.<\/p>\n<\/td>\n<\/tr>\n\n\n

Natera, Inc.<\/b><\/p>\n<\/td>\n\n

Presented ASCO\u202f2025 data highlighting pan-cancer Signatera MRD
\n sensitivity at 94% and specificity at 100%, and expanded soft\u2011tissue sarcoma
\n validation.<\/p>\n<\/td>\n<\/tr>\n

\u00a0<\/p>\n

Clinical Genomics Market Companies:<\/b><\/p>\n

<\/b><\/p>\n

\u2022\u00a0 Illumina, Inc.<\/p>\n

\u2022\u00a0 Quest Diagnostics Incorporated<\/p>\n

\u2022\u00a0 PerkinElmer, Inc.<\/p>\n

\u2022\u00a0 Eurofins Scientific SE<\/p>\n

\u2022 \u00a0Rosetta Genomics Ltd.<\/p>\n

\u2022\u00a0 NeoGenomics Inc.<\/p>\n

\u2022\u00a0 Invitae Corporation<\/p>\n

\u2022\u00a0 Foundation Medicine, Inc.<\/p>\n

\u2022\u00a0 Genomic Health, Inc.<\/p>\n

\u2022\u00a0 Natera, Inc.<\/p>\n

\u2022\u00a0 Myriad Genetics, Inc.<\/p>\n

\u2022\u00a0 Clinical Genomics Pty Ltd.<\/p>\n

\u2022\u00a0 OPKO Health, Inc.<\/p>\n

\u2022\u00a0 23andMe, Inc.<\/p>\n

\u2022\u00a0 Centogene AG<\/p>\n

\u2022\u00a0 Gene by Gene, Ltd.<\/p>\n

\u2022\u00a0 Iverson Genetic Diagnostics, Inc.<\/p>\n

\u2022\u00a0 GenomeDx Biosciences, Inc.<\/p>\n

\u2022\u00a0 PathGroup<\/p>\n

\u2022\u00a0 Veritas Genetics<\/p>\n

\u2022\u00a0 Personalis, Inc.<\/p>\n

\u2022\u00a0 MedGenome<\/p>\n

\u2022\u00a0 Strand Life Sciences Pvt. Ltd.<\/p>\n

\u2022\u00a0 Retrogen, Inc.<\/p>\n

\u2022\u00a0 Beijing Genomics Institute (BGI)<\/p>\n

What is Going Around the Globe?<\/b><\/p>\n

\u2022\u00a0 In April 2025, Fortis Healthcare, a
\nhealthcare company, launched the Genomic Medicine Institute in India.<\/p>\n

\u2022\u00a0 In April 2025, Natera, Inc., a leading
\nplayer in cell-free DNA and genetic testing, announced that its ultra-sensitive
\nSignatera Genome assay is widely available to physicians in the United States.<\/p>\n

\u2022\u00a0 In April 2025, Exact Sciences, a major
\nprovider of cancer screening and diagnostic tests, launched Oncodetect, an
\ninnovative test designed to detect molecular residual disease (MRD) across multiple
\nsolid tumors.\u00a0<\/p>\n

\u2022\u00a0 In February 2025, GeneDx, a genetic
\ntesting company, launched ultrarapid whole genome sequencing for critically ill
\ninfants.<\/p>\n

\u2022\u00a0 In February 2025, Strand Life Sciences
\nunveiled a portal for rare disease diagnosis, with affordable genetic testing.<\/p>\n

\u2022\u00a0 In June 2024, Helix, a global player in
\ngenomic companies, launched a novel clinico-genomic dataset for cardiovascular,
\nmetabolic, immunology, and inflammation disorders.<\/p>\n

Clinical Genomics Market Segmentation<\/b><\/p>\n

By Test Type<\/b><\/p>\n

\u2022\u00a0 Diagnostic Testing<\/p>\n

\u2022\u00a0 Genetic Testing<\/p>\n

\u2022\u00a0 Newborn Screening<\/p>\n

\u2022\u00a0 Preimplantation Testing<\/p>\n

\u2022\u00a0 Prenatal Testing<\/p>\n

\u2022\u00a0 Carrier Testing<\/p>\n

\u2022\u00a0 Other Tests<\/p>\n

By Method<\/b><\/p>\n

\u2022\u00a0 Molecular Tests<\/p>\n

\u2022\u00a0 Chromosomal Tests<\/p>\n

\u2022\u00a0 Biochemical Tests<\/p>\n

By End User<\/b><\/p>\n

\u2022\u00a0 Hospitals & Clinics<\/p>\n

\u2022\u00a0 Government Laboratories & Research
\nCentres<\/p>\n

\u2022\u00a0 Academics and Research Institutes<\/p>\n

\u2022\u00a0 Other End Users<\/p>\n

By Region<\/b><\/p>\n

\u2022\u00a0 North America<\/p>\n

\u2022\u00a0 U.S.<\/p>\n

\u2022\u00a0 Canada<\/p>\n

\u2022\u00a0 Asia Pacific<\/p>\n

\u2022\u00a0 China<\/p>\n

\u2022\u00a0 Japan<\/p>\n

\u2022\u00a0 India<\/p>\n

\u2022\u00a0 South Korea<\/p>\n

\u2022\u00a0 Thailand<\/p>\n

\u2022\u00a0 Europe<\/p>\n

\u2022\u00a0 Germany<\/p>\n

\u2022\u00a0 UK<\/p>\n

\u2022\u00a0 France<\/p>\n

\u2022\u00a0 Italy<\/p>\n

\u2022\u00a0 Spain<\/p>\n

\u2022\u00a0 Sweden<\/p>\n

\u2022\u00a0 Denmark<\/p>\n

\u2022\u00a0 Norway<\/p>\n

\u2022\u00a0 Latin America<\/p>\n

\u2022\u00a0 Brazil<\/p>\n

\u2022\u00a0 Mexico<\/p>\n

\u2022\u00a0 Argentina<\/p>\n

\u2022\u00a0 Middle East and Africa (MEA)<\/p>\n

\u2022\u00a0 South Africa<\/p>\n

\u2022\u00a0 UAE<\/p>\n

\u2022\u00a0 Saudi Arabia<\/p>\n

\u2022\u00a0 Kuwait<\/p>\n

Unlock the complete Clinical Genomics
\nMarket report with in-depth analysis, forecasts, and competitive landscape: <\/b><\/a>https:\/\/www.towardshealthcare.com\/price\/5754<\/b><\/a><\/p>\n

You can place an order or ask any
\nquestions, please feel free to contact us at <\/b>sales@towardshealthcare.com<\/b><\/a><\/p>\n

Gain access to the
\nlatest insights and statistics in the healthcare industry by subscribing to our
\nAnnual Membership. Stay updated on healthcare industry segmentation with
\ndetailed reports, market trends, and expert analysis tailored to your needs.
\nStay ahead of the curve with valuable resources and strategic recommendations.
\nJoin today to unlock a wealth of knowledge and opportunities in the dynamic
\nworld of healthcare: <\/b>Get a Subscription<\/b><\/a><\/p>\n

About Us<\/b><\/p>\n

Towards
\nHealthcare<\/b><\/a> is a leading global provider of
\ntechnological solutions, clinical research services, and advanced analytics,
\nwith a strong emphasis on life science research<\/b><\/a>. Dedicated to advancing innovation in the life sciences sector, we
\nbuild strategic partnerships that generate actionable insights and
\ntransformative breakthroughs. As a global strategy consulting firm, we empower
\nlife science leaders to gain a competitive edge, drive research excellence, and
\naccelerate sustainable growth.<\/p>\n

Our Trusted Data Partners<\/b><\/p>\n

Precedence Research<\/b><\/a> | <\/b>Statifacts<\/b><\/a> | <\/b>Towards Packaging<\/b><\/a> | <\/b>Towards
\nAutomotive<\/b><\/a> | <\/b>Towards Food and
\nBeverages<\/b><\/a> | <\/b>Towards
\nChemical and Materials<\/b><\/a> | <\/b>Towards Consumer
\nGoods<\/b><\/a> | <\/b>Towards Dental<\/b><\/a> | <\/b>Towards EV Solutions<\/b><\/a> | <\/b>Nova One Advisor<\/b><\/a> | <\/b>Healthcare Webwire<\/b><\/a> | <\/b>Packaging Webwire<\/b><\/a> | <\/b>Automotive Webwire<\/b><\/a><\/p>\n

For Latest Update Follow Us: <\/b>https:\/\/www.linkedin.com\/company\/towards-healthcare<\/b><\/a> <\/b><\/p>\n

Browse More Insights of Towards
\nHealthcare<\/b><\/a>:<\/b><\/p>\n

Genomic
\nUrine Testing Market<\/a><\/b><\/p>\n

Metagenomics
\nMarket<\/b><\/a><\/p>\n

Consumer
\nGenomics Market<\/b><\/a><\/p>\n

Preclinical
\nAdvanced Cell Models Market<\/b><\/a><\/p>\n

AI
\nin Clinical Trials for Drugs Market<\/b><\/a><\/p>\n

Clinical
\nData Analytics Market<\/b><\/a><\/p>\n

Clinical
\nTrial Design Market<\/b><\/a><\/p>\n

Clinical
\nTrial Biorepository and Archiving Solutions Market<\/b><\/a><\/p>\n

Preclinical
\nCRO Market<\/b><\/a><\/p>\n

Clinical
\nTrial Investigative Site Network Market<\/b><\/a><\/p>\n

Clinical
\nTrial Supply and Logistics Market<\/b><\/a><\/p>\n

Circulating
\nTumor Cells Market<\/b><\/a><\/p>\n

Clinical
\nMicrobiology Market<\/b><\/a><\/p>\n

AI
\nin Medical Imaging Market<\/b><\/a><\/p>\n

Decentralized
\nClinical Trials (DCTs) Market<\/b><\/a><\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"The global clinical genomics market is valued at approximately US$1.06 billion in 2024 and is expected to rise…\n","protected":false},"author":2,"featured_media":231278,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[267,70,16,15],"class_list":{"0":"post-231277","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114782176862378462","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/231277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=231277"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/231277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/231278"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=231277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=231277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=231277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}